Nuclear Magnetic Resonance (NMR) Spectroscopy is a non-destructive analytical technique that is used to study the nature and characteristics of molecules with an atomic level precision. It has a wide range of applications especially in synthetic chemistry, biological and biochemical research groups…

Researchers from Leiden University Medical Center (LUMC) and the Leiden-based biotech company Ncardia have joined forces to develop a new platform that enables the automated production of 3D cardiac microtissues. This platform will allow large numbers of drugs to be tested quickly

Providing each cancer patient with the right treatment remains a challenge. Oncode Accelerator aims to change this by innovating the way we develop cancer treatments, thus ensuring the patient is at the heart of the process.

How can we prevent drug-induced liver and kidney damage? PhD candidates Marije Niemeijer and Lukas Wijaya investigated what happens in the cells during the onset of this damage: a stress response. Both focused on a different subtopic and made some interesting discoveries.

Bioprinters that enable scientists to engineer complex tissues and organs. It sounds like science-fiction, but not for the scientists of the Alireza Mashaghi lab at the Leiden Academic Centre for Drug Research. The lab has recently been equipped with two state-of-the-art bioprinters: BioX and LumenX+.…

This thesis pioneers diatom molecular identification and quantification through genome-scale methods, with four key aims: (i) reviewing DNA/RNA sequencing methods in aquatic biomonitoring to highlight their strengths and limitations;

University lecturer Steven Lauritano has been awarded a Comenius Teaching Fellow grant. Lauritano will use the grant of 50,000 euros to improve hybrid education in classes featuring particular objects.

Many pharmaceutical companies no longer have their own lab and are working more closely with universities and start-ups of scientists. Professor of Science-Based Business Simcha Jong is researching how scientific ideas result in new drugs, including at the Leiden Bio Science Park (LBSP).

This thesis focuses on enhancing predictions of central nervous system drug exposure using the LeiCNS-PK3.0, a physiologically based pharmacokinetic model.

Global healthcare is on the verge of an antibiotic availability crisis as bacteria have evolved resistance to nearly all known antibacterials. Identifying new antibiotics that operate via novel modes-of-action is therefore of high priority.

Bringing your drug candidates to patients is what many academic chemists dream about, but the road to this goal is long and bumpy. Now, Leiden small molecule nizubaglustat is ready for phase 3 clinical trials. This is thanks to a €132 million funding secured by the biotech spin-out Azafaros.

Nature Reviews Drug Discovery volume 18, pages 82–84 (2019). The implications of target saturation for the use of drug–target residence time Wilbert de Witte, Meindert Danhof, Piet van der Graaf, and Elizabeth de Lange

Discovering effective new drugs is a long, expensive and uncertain process. Laura Heitman wants to improve this by finding out more about how drugs bind to proteins that play a role in disease. She calls it ‘drug discovery 3.0’. Inaugural lecture on 9 December.

Light can be used to apply forces on single cells. Focused lasers have been used by physicists to tweeze particles and to manipulate them. These so called “optical tweezers” can be used as mechanical phenotyping tools for characterising the mechanics of materials and living objects.

Promotor: M. Danhof, Co-promotores: J. Freijer, A. Yassen

Sugar excipients, needed to stabilize medicines, can be unsafe for patients due to an impurity discovered recently by Daniel Weinbuch. ‘The biopharmaceutical industry should now consider new excipient quality criteria for safer drug development,’ he says. PhD defence on 13 December.

On the 6th of March 2023, Santino Regilme presented his work-in-progress titled 'Global Drug Wars: Contested Normative Orders of Peace, Security, and Human Rights'. If the battle against illegal drugs is construed as a war, how is victory in such a war defined and constructed? If the oppositional…

Research conducted at Leiden has established that guts-on-chips respond in the same way to aspirin as real human organs do. This is a sign that these model organs are good predictors of the effect of medical drugs on the human body. Publication in Nature Communications on 15 August.

Do medicines arrive in the right amount at the right spot in our brain? By making a model that depicts our brain in small 'brain blocks', Esmée Vendel tries to find an answer to this question. Her new, mathematical model predicts the concentration of medicines in the brain over time and space. Vendel…

It takes years to develop new medicines, from the test tube to trials in humans. During the process it often happens that a drug that seems promising in the initial stage has to be dropped in a later phase. This costs time and money. Leiden University and the LUMC are working closely together to make…

Cancer research generates massive amounts of data, but traditional tools often fail to fully harness their potential. How can we unlock this data to provide better treatments for cancer patients? PhD candidate Marina Gorostiola González explored this by using advanced data analysis techniques to guide…

Triple-negative breast cancer (TNBC) is a subtype of breast cancer characterized by limited treatment options and unfavorable clinical outcomes. Therefore, the research described in this thesis focused on the exploration of novel targeted therapies for TNBC.

From studying molecules in the blood of corona patients to developing a new concept for vaccines. The Leiden Academic Centre for Drug Research (LACDR) has transformed many ongoing projects into Covid research projects. Hubertus Irth, scientific director of LACDR, talks about the role of his institute…

Promotores: Prof.dr. J. A. Bouwstra, Prof.dr. W. Jiskoot

As of April 1, 2018, Erik Danen has been appointed as Professor of Cancer drug target discovery at the Leiden Academic Centre for Drug Research (LACDR). His discipline is cell biology of cancer, in which he focuses on the mechanisms underlying metastasis and therapy resistance.

Nerve pain is one of the most common side effects of chemotherapy. It is therefore one of the biggest reasons for cancer patients to stop treatment early. Darcy Reynolds worked on new drug candidates against this pain during her bachelor's thesis. She developed a new series of molecules that increase…

In health care, artificial intelligence is quite normal: it is used, for example, as an aid in making diagnoses. However, artificial intelligence is not yet used as much in drug development. A new prestigious partnership is therefore going to investigate how artificial intelligence can contribute to…

Actin and microtubules form cellular cytoskeletal network, which mediates cell shape, motility and proliferation and are key targets for cancer therapy. Changes in cytoskeletal organization correlate with proliferative capacity and invasiveness of cancer cells. These changes expectedly lead to altered…

Triplet superconductivity refers to a condensate of equal-spin Cooper pairs (pairs of electrons with equal spin).

The aim of this work was to study the applicability of antigen-coated pH-sensitive microneedle arrays for effective vaccination strategies. Therefore, a model antigen (ovalbumin) was coated onto pH-sensitive (pyridine-modified) microneedle arrays to test pH-triggered antigen release by applying the…

Chemist Tobias Bauer discovered ways to improve drugs by encapsulating them. Packages with iron nanoparticles, for example, can stimulate immune cells. Bauer will receive his PhD on 9 June.

The Leiden Academic Centre for Drug Research (LACDR) has received a €750,000 grant from ZonMw for QPharmNL. This is a continuing education programme that trains professionals in computational techniques in pharmacology for innovative drug development.

The intradermal administration route is attractive for vaccine delivery, because of the highly populated antigen-presenting cells in the skin. However, the skin’s main physical barrier, the stratum corneum, prevents vaccines from entering the skin.

This thesis tackles the difficulty of predicting the liver’s clinical response to novel therapies, a challenge arising from interspecies differences and limitations of existing in vitro models.

Endocannabinoids - the body's own marijuana - are promising departure points for drug research. Professor of Molecular Physiology Mario van der Stelt examines whether inhibiting their production can be a way to fight inflammatory brain disease and to combat obesity. Inaugural lecture 19 October.

International pharmaceuticals company Grünenthal is to open an innovation hub on the Leiden Bio Science Park. The hub will make it easier for scientists and drug developers to work together.

Promotor: B. van de Water

In this thesis population pharmacokinetic and physiologically-based pharmacokinetic (PBPK) approaches were applied to investigate the influence of glomerular filtration (GF) and active tubular secretion (ATS) on renal clearance in children.

In this project, researchers from computer science, law, psychology, and public administration research in practice how artificial intelligence (AI) can be leveraged to make decision-making in the security domain more effective, while also keeping it safe and accountable.

Solute carrier (SLC) transporters are a large and diverse class of relatively understudied transmembrane proteins.

Triple-negative breast cancer (TNBC) constitutes a small subtype (~15%) of breast cancer, but causes the majority of breast cancer-related deaths.

Promotor: M. Ubbink, Co-promotor: G. Siegal

Promotores: A.P. IJzerman, H.W.T. van Vlijmen

The cannabinoid receptor type 2 (CB2R) is associated with several inflammatory diseases with an unmet medical need (e.g. Alzheimers, multiple sclerosis, reumatoid arthritis). Development of new chemical biology strategies to study this protein is essential to aid future development of drugs for these…

The Delivery of Biotherapeutics research group is led by Prof. Matthias Barz and focusses on the synthesis and characterization of polypept(o)ids and their application in nanomedicine to improve existing therapies or enable novel diagnostic or therapeutic approaches.